Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 5Active not recruiting 2Terminated 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Dermatologic 1

Conditions

Melanoma 1Advanced Malignant Solid Neoplasm 1

Interventions

Specimen Handling 188Magnetic Resonance Spectroscopy 143Biopsy 116Nivolumab 39X-Rays 29Immunoglobulin G 29Disulfides 29Radiation 28Carboplatin 27atezolizumab 25Taxes 25Paclitaxel 25pembrolizumab 23Radiotherapy 23Ipilimumab 23CTLA-4 Antigen 23olaparib 22Cyclophosphamide 22Cisplatin 21Platinum 20Gemcitabine 20Doxorubicin 20Bevacizumab 201,2-diaminocyclohexaneplatinum II citrate 20Phantoms, Imaging 19Vincristine 17trametinib 16cabozantinib 15Rituximab 15ibrutinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × NIH × dinaciclib × Clear all
NCT00937937 2026-05-29

Dinaciclib in Treating Patients With Stage IV Melanoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
72 enrolled 14 charts
Dermatologic

Melanoma

NCT01434316 2026-04-13

Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
121 enrolled
Other solid neoplasm

Advanced Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡